Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05502250
Title Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (HOVON164HL)
Acronym HOVON164HL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Age Groups: adult | senior
Covered Countries NLD | BEL

No variant requirements are available.